Doxt SL: Advanced Dual-Action Therapy for Respiratory Relief
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $2.21 | $44.13 (0%) | 🛒 Add to cart |
| 30 | $1.67 | $66.19 $50.15 (24%) | 🛒 Add to cart |
| 60 | $1.05 | $132.39 $63.18 (52%) | 🛒 Add to cart |
| 90 | $0.87 | $198.58 $78.23 (61%) | 🛒 Add to cart |
| 120 | $0.69 | $264.77 $82.24 (69%) | 🛒 Add to cart |
| 180 | $0.59 | $397.16 $106.31 (73%) | 🛒 Add to cart |
| 270 | $0.50 | $595.74 $135.39 (77%) | 🛒 Add to cart |
| 360 | $0.45
Best per pill | $794.32 $162.47 (80%) | 🛒 Add to cart |
Doxt SL is a prescription medication expertly formulated to provide comprehensive management of chronic obstructive pulmonary disease (COPD) and related respiratory conditions. Combining two active ingredients with complementary mechanisms, it works to reduce bronchospasm, decrease mucus secretion, and improve overall lung function. This fixed-dose combination is designed for long-term maintenance therapy, helping patients achieve better control over symptoms and enhance quality of life. Trusted by pulmonologists worldwide, Doxt SL represents a cornerstone in modern respiratory pharmacotherapy.
Features
- Contains a precise blend of Doxofylline and Salbutamol
- Available in sustained-release tablet form for prolonged effect
- Manufactured under strict pharmaceutical quality standards
- Precisely calibrated dosage strengths for optimal therapeutic effect
- Bioequivalent to reference listed drugs with established bioavailability
- Packaged in blister strips to ensure stability and ease of use
Benefits
- Provides dual bronchodilation through phosphodiesterase inhibition and beta-2 adrenergic agonism
- Reduces frequency and severity of acute exacerbations in COPD patients
- Improves exercise tolerance and daily activity performance
- Decreases airway resistance and enhances mucociliary clearance
- Offers convenient twice-daily dosing for improved adherence
- Demonstrates favorable safety profile with minimal cardiovascular effects compared to traditional theophylline preparations
Common use
Doxt SL is primarily indicated for the maintenance treatment of chronic obstructive pulmonary disease, including emphysema and chronic bronchitis. It may be prescribed as part of comprehensive management for reversible airway obstruction in asthma patients when combination therapy is warranted. The medication is typically used for long-term control rather than immediate relief of acute bronchospasm. Healthcare providers may also consider Doxt SL for patients who require both bronchodilator and anti-inflammatory effects but need to avoid corticosteroid therapy.
Dosage and direction
The recommended adult dosage is one tablet twice daily, approximately every 12 hours. Tablets should be swallowed whole with a glass of water and should not be crushed or chewed. Dosage may be adjusted based on individual patient response, severity of condition, and hepatic function. Administration with food may help minimize potential gastrointestinal discomfort. Patients should maintain consistent timing of doses to ensure stable therapeutic levels. Dose titration should be supervised by a healthcare professional, with regular assessment of clinical response and potential side effects.
Precautions
Patients with cardiovascular disorders, particularly arrhythmias, should use Doxt SL with caution and undergo regular monitoring. Hepatic impairment requires dosage adjustment and careful supervision. Diabetic patients should monitor blood glucose levels as beta-agonists may affect glucose metabolism. Elderly patients may require lower doses due to decreased clearance. Use with caution in patients with hyperthyroidism, peptic ulcer disease, or seizure disorders. Patients should be advised that Doxt SL is not for immediate relief of acute attacks and should have rescue medication available.
Contraindications
Hypersensitivity to doxofylline, salbutamol, or any component of the formulation. Contraindicated in patients with tachyarrhythmias, severe cardiac disease, or uncontrolled hypertension. Should not be used in cases of porphyria or during acute myocardial infarction. Concurrent administration with non-selective beta-blockers is contraindicated. Not recommended for patients with severe hepatic impairment without appropriate dosage adjustment and monitoring.
Possible side effect
Common side effects may include headache, nausea, gastrointestinal discomfort, tremors, palpitations, and nervousness. Less frequently, patients may experience insomnia, dizziness, increased heart rate, or muscle cramps. Rare but serious side effects include cardiac arrhythmias, significant hypokalemia, paradoxical bronchospasm, and allergic reactions. Most side effects are dose-dependent and often diminish with continued therapy. Patients should report persistent or severe side effects to their healthcare provider promptly.
Drug interaction
Methylxanthines may interact with fluoroquinolone antibiotics, macrolides, allopurinol, and cimetidine, potentially increasing theophylline levels. Beta-agonists may potentiate effects of other sympathomimetic agents. Concurrent use with diuretics may increase the risk of hypokalemia. Monoamine oxidase inhibitors and tricyclic antidepressants may potentiate cardiovascular effects. Theophylline may decrease lithium levels and increase the elimination of benzodiazepines. Healthcare providers should review all concomitant medications before prescribing Doxt SL.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Patients should not double the dose to make up for a missed administration. Consistent adherence to the prescribed regimen is important for maintaining therapeutic blood levels and optimal control of respiratory symptoms.
Overdose
Symptoms of overdose may include severe nausea and vomiting, cardiac arrhythmias, hypotension, hypokalemia, hyperglycemia, seizures, and metabolic acidosis. Management involves immediate discontinuation of the medication, supportive care, and symptomatic treatment. Activated charcoal may be administered if ingestion was recent. Cardiac monitoring is essential, and specific treatments for arrhythmias or seizures may be required. Serum theophylline levels should be measured to guide management decisions.
Storage
Store at room temperature (15-30°C) in a dry place protected from light and moisture. Keep in the original packaging until time of use. Do not remove tablets from blister strips until immediately before administration. Keep out of reach of children and pets. Do not use after the expiration date printed on the packaging. Proper storage conditions are essential for maintaining drug stability and efficacy throughout the shelf life.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Doxt SL is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Patients should not initiate or discontinue therapy without consulting their physician. The prescribing information provided here may not include all possible uses, directions, precautions, or interactions. Always refer to the official prescribing information and consult with a healthcare provider for personalized medical advice.
Reviews
Clinical studies demonstrate that Doxt SL provides significant improvement in pulmonary function tests and quality of life scores in COPD patients. Physicians report satisfactory patient tolerance and improved symptom control compared to monotherapy approaches. Patients note reduced rescue medication use and better ability to perform daily activities. Long-term follow-up studies indicate maintained efficacy with consistent dosing. The combination therapy has shown particular benefit for patients who require sustained bronchodilation with reduced side effect burden compared to traditional theophylline preparations.